Oral GLP-1 prescriptions climb for Novo's Wegovy pill and Lilly's Foundayo
Fierce Pharma's tracker shows both oral incretin products continuing to gain scripts after launch.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 11 03:00 ETSource: Fierce Pharma
The wire
- 01Fierce Pharma's oral GLP-1 tracker reports continued prescription growth for Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo.
- 02Oral incretin uptake affects injectable demand, compounding volumes and telehealth formularies built around subcutaneous semaglutide and tirzepatide.
- 03The tracker reflects script trends only; it does not address payer coverage, persistence or net pricing behind the volumes.
From the source
Read at fiercepharma.comThe Oral GLP-1 Tracker: Novo's Wegovy pill, Lilly's Foundayo continue prescription climb